Inhibitors in haemophilia: clinical aspects

Abstract

Inhibitor development continues to be a severe complication worldwide of haemophilia therapy. Given the difficulties associated with the treatment of inhibitors in both the developed and the developing world, prediction and prevention of inhibitors following exposure to factor VIII or IX in the young child has become a management priority. Two different clinical approaches to minimizing or delaying inhibitor development are highlighted in this manuscript. Challenges in the therapy of existing inhibitors persist. However, the nature of the issues faced by physicians in the developed and developing worlds vary considerably. Both are discussed in this manuscript by representatives of both worlds, who face these challenges on a daily basis.Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USASt Justine Hosp, Dept Hematol, Montreal, PQ, CanadaManchester Royal Infirm, Dept Clin Haematol, Manchester M13 9WL, Lancs, EnglandUniversidade Federal de São Paulo, Serv Hemofilia, São Paulo, BrazilUniversidade Federal de São Paulo, Serv Hemofilia, São Paulo, BrazilWeb of Scienc